Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents)
  4. Volume 24, Issue 1
  5. Article
Volume 24, Issue 1
  • ISSN: 1871-5230
  • E-ISSN: 1875-614X

Abstract

This review seeks to assess the potential of nanomaterials, specifically Nano-structured Lipid Carriers (NLCs), in mitigating challenges associated with inflammation-related disorders, with a particular emphasis on chronic ailments like arthritis. A comprehensive literature review spanning Web of Science, PubMed, and other scholarly repositories from 2000 to 2023 is conducted. Articles are selected based on their focus on NLCs and inflammation management, utilizing keywords, such as “nanomaterials,” “targeted drug delivery,” and “arthritis.” Exclusion criteria involve non-English studies or those lacking adequate detail on NLCs. Synthesized data provide an overview of the advantages, challenges, and prospects of NLCs in addressing chronic inflammatory disorders. This review also examines the therapeutic applications of nanotechnology, including targeted drug delivery and tissue engineering, particularly focusing on the intricate biological responses in chronic inflammation, often involving Non-steroidal Anti-inflammatory Drugs (NSAIDs). Moreover, the exploration extends to topical delivery methods to enhance control over medication concentration, with a review of lipid nanoparticles, such as liposomes and solid-lipid nanoparticles, highlighting their potential in augmenting drug permeation while addressing challenges like inadequate drug loading.

NLCs have emerged as promising candidates for overcoming drug delivery challenges, particularly in arthritis treatment, with a focus on their advantages across diverse lipid compositions. The review underscores significant strides in inflammation management through NLC utilization, offering insights into future research directions.

Moreover, it contributes to ongoing advancements in nanomedicine, emphasizing the pivotal role of NLCs in developing innovative therapeutic approaches for inflammation-related disorders, particularly arthritis. NLCs represent a promising avenue for effective interventions, signaling progress in nanotechnology-enabled therapeutics.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/aiaamc/10.2174/0118715230311633240708075738
2024-07-30
2025-05-13

  • From This Site

    /content/journals/aiaamc/10.2174/0118715230311633240708075738
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. TaniguchiN. On the basic concept of nanotechnology.Proceedings of the International Conference on Production Engineering. Tokyo: Japan Society of Precision Engineering19741823
     [Google Scholar]
  2. KhanI. SaeedK. KhanI. Nanoparticles: Properties, applications and toxicities.Arab. J. Chem.201912790893110.1016/j.arabjc.2017.05.011
     [Google Scholar]
  3. Tovar-LopezF.J. Recent progress in micro-and nanotechnology-enabled sensors for biomedical and environmental challenges.Sensors20232312540610.3390/s23125406 37420577
     [Google Scholar]
  4. ChauhanV. SinghV. TiwariA. Applications of nanotechnology in forensic investigation. Int. J. Life.Sci. Scienti. Res20173310471051
     [Google Scholar]
  5. Abdel-MageedH.M. AbuelEzz, N.Z.; Radwan, R.A.; Mohamed, S.A. Nanoparticles in nanomedicine: A comprehensive updated review on current status, challenges and emerging opportunities.J. Microencapsul.202138641443610.1080/02652048.2021.1942275 34157915
     [Google Scholar]
  6. PatraJ.K. DasG. FracetoL.F. CamposE.V.R. Rodriguez-TorresM.P. Acosta-TorresL.S. Diaz-TorresL.A. GrilloR. SwamyM.K. SharmaS. HabtemariamS. ShinH.S. Nano based drug delivery systems: Recent developments and future prospects.J. Nanobiotechnology20181617110.1186/s12951‑018‑0392‑8 30231877
     [Google Scholar]
  7. ChenL. DengH. CuiH. FangJ. ZuoZ. DengJ. LiY. WangX. ZhaoL. Inflammatory responses and inflammation-associated diseases in organs.Oncotarget2018967204721810.18632/oncotarget.23208 29467962
     [Google Scholar]
  8. AbdulkhaleqL.A. AssiM.A. AbdullahR. Zamri-SaadM. Taufiq-YapY.H. HezmeeM.N.M. The crucial roles of inflammatory mediators in inflammation: A review.Vet. World201811562763510.14202/vetworld.2018.627‑635 29915501
     [Google Scholar]
  9. SinghA. DasS. ChopraA. DandaD. PaulB.J. MarchL. MathewA.J. ShenoyP. GotayC. PalmerA.J. AntonyB. Burden of osteoarthritis in India and its states, 1990–2019: Findings from the Global Burden of disease study 2019.Osteoarthritis Cartilage20223081070107810.1016/j.joca.2022.05.004 35598766
     [Google Scholar]
  10. Brennan-OlsenS.L. CookS. LeechM.T. BoweS.J. KowalP. NaidooN. AckermanI.N. PageR.S. HoskingS.M. PascoJ.A. MohebbiM. Prevalence of arthritis according to age, sex and socioeconomic status in six low and middle income countries: Analysis of data from the World Health Organization study on global AGEing and adult health (SAGE) Wave 1.BMC Musculoskelet. Disord.201718127110.1186/s12891‑017‑1624‑z 28633661
     [Google Scholar]
  11. SuzukiK. Chronic inflammation as an immunological abnormality and effectiveness of exercise.Biomolecules20199622310.3390/biom9060223 31181700
     [Google Scholar]
  12. BinduS. MazumderS. BandyopadhyayU. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective.Biochem. Pharmacol.202018011414710.1016/j.bcp.2020.114147 32653589
     [Google Scholar]
  13. HanF. YinR. CheX. YuanJ. CuiY. YinH. LiS. Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: Design, characterization and in vivo evaluation.Int. J. Pharm.20124391-234935710.1016/j.ijpharm.2012.08.040 22989987
     [Google Scholar]
  14. GhasemiyehP. Mohammadi-SamaniS. Potential of nanoparticles as permeation enhancers and targeted delivery options for skin: Advantages and disadvantages.Drug Des. Devel. Ther.2020143271328910.2147/DDDT.S264648 32848366
     [Google Scholar]
  15. ViegasC. PatrícioA.B. PrataJ.M. NadhmanA. ChintamaneniP.K. FonteP. Solid lipid nanoparticles vs. Nanostructured lipid carriers: A comparative review.Pharmaceutics2023156159310.3390/pharmaceutics15061593 37376042
     [Google Scholar]
  16. JavedS. ManglaB. AlmoshariY. SultanM.H. AhsanW. Nanostructured lipid carrier system: A compendium of their formulation development approaches, optimization strategies by quality by design, and recent applications in drug delivery.Nanotechnol. Rev.20221111744177710.1515/ntrev‑2022‑0109
     [Google Scholar]
  17. SharmaA. BaldiA. Nanostructured lipid carriers: A review.J. Dev. Drugs2018721000191
     [Google Scholar]
  18. ElmowafyM. Al-SaneaM.M. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies.Saudi Pharm. J.2021299999101210.1016/j.jsps.2021.07.015 34588846
     [Google Scholar]
  19. JenningV. MäderK. GohlaS.H. Solid lipid nanoparticles (SLN™) based on binary mixtures of liquid and solid lipids: A 1H-NMR study.Int. J. Pharm.20002051-2152110.1016/S0378‑5173(00)00462‑2 11000538
     [Google Scholar]
  20. ShahR. EldridgeD. PalomboE. HardingI. Lipid nanoparticles: Production, characterization and stability.Springer201510.1007/978‑3‑319‑10711‑0
     [Google Scholar]
  21. JenningV. Schäfer-KortingM. GohlaS. Vitamin A-loaded solid lipid nanoparticles for topical use: Drug release properties.J. Control. Release2000662-311512610.1016/S0168‑3659(99)00223‑0 10742573
     [Google Scholar]
  22. SoniK. KukerejaB.K. KapurM. KohliK. Lipid nanoparticles: Future of oral drug delivery and their current trends and regulatory issues.Int. J. Curr. Pharm. Rew. Res.20157118
     [Google Scholar]
  23. WissingS.A. MüllerR.H. The influence of the crystallinity of lipid nanoparticles on their occlusive properties.Int. J. Pharm.20022421-237737910.1016/S0378‑5173(02)00220‑X 12176283
     [Google Scholar]
  24. ChenP.C. HuangJ.-W. PangJ. An investigation of optimum NLC-sunscreen formulation using Taguchi analysis.J. Nanomater.2013201310.1155/2013/463732
     [Google Scholar]
  25. JoshiM. PatravaleV. Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of Valdecoxib.Drug Dev. Ind. Pharm.200632891191810.1080/03639040600814676 16954103
     [Google Scholar]
  26. LasońE. SikoraE. OgonowskiJ. Influence of process parameters on properties of nanostructured lipid carriers (NLC) formulation.Acta Biochim. Pol.2013604773777 24432330
     [Google Scholar]
  27. NairR. Arun KumarK. Vishnu PriyaK. SevukarajanM. Recent advances in solid lipid nanoparticle based drug delivery systems.J. Biomed. Sci. Res.201132368384
     [Google Scholar]
  28. SutorminO.S. KolosovaE.M. TorgashinaI.G. KratasyukV.A. KudryashevaN.S. KinstlerJ.S. StomD.I. Toxicity of different types of surfactants via cellular and enzymatic assay systems.Int. J. Mol. Sci.202224151510.3390/ijms24010515 36613956
     [Google Scholar]
  29. DhimanN. AwasthiR. SharmaB. KharkwalH. KulkarniG.T. Lipid nanoparticles as carriers for bioactive delivery.Front Chem.2021958011810.3389/fchem.2021.580118 33981670
     [Google Scholar]
  30. BoafoG.F. MagarK.T. EkpoM.D. QianW. TanS. ChenC. The role of cryoprotective agents in liposome stabilization and preservation.Int. J. Mol. Sci.202223201248710.3390/ijms232012487 36293340
     [Google Scholar]
  31. JenningV. GohlaS. Comparison of wax and glyceride solid lipid nanoparticles (SLN®).Int. J. Pharm.2000196221922210.1016/S0378‑5173(99)00426‑3 10699722
     [Google Scholar]
  32. ArunkumarN. DeecaramanM. RaniC. Nanosuspension technology and its applications in drug delivery.Asian J. Pharm.20093316810.4103/0973‑8398.56293
     [Google Scholar]
  33. ÜnerM. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): Their benefits as colloidal drug carrier systems.Pharmazie2006615375386 16724531
     [Google Scholar]
  34. KadamV. DhanawadeK. SalunkheV. UbaleA. Nanoparticle-novel drug delivery system.J. Curr. Pharma Res.2014441318133510.33786/JCPR.2014.v04i04.009
     [Google Scholar]
  35. ÜnerM. YenerG. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives.Int. J. Nanomedicine200723289300 18019829
     [Google Scholar]
  36. DuongV.A. NguyenT.T.L. MaengH.J. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method.Molecules20202520478110.3390/molecules25204781 33081021
     [Google Scholar]
  37. RacovitaR.C. CiucaM.D. CatanaD. ComanescuC. CiocirlanO. Microemulsions of nonionic surfactant with water and various homologous esters: Preparation, phase transitions, physical property measurements, and application for extraction of tricyclic antidepressant drugs from aqueous media.Nanomaterials20231316231110.3390/nano13162311 37630897
     [Google Scholar]
  38. YadavK.S. SoniG. ChoudharyD. KhanduriA. BhandariA. JoshiG. Microemulsions for enhancing drug delivery of hydrophilic drugs: Exploring various routes of administration.Med. Drug Discov.20232010016210.1016/j.medidd.2023.100162
     [Google Scholar]
  39. JohnR. MonparaJ. SwaminathanS. KalhapureR. Chemistry and art of developing lipid nanoparticles for biologics delivery: Focus on development and scale-up.Pharmaceutics202416113110.3390/pharmaceutics16010131 38276502
     [Google Scholar]
  40. KHARWADER.S. Formulation and evaluation of nanostructured lipid carriers based anti-inflammatory gel for topical drug delivery system.Asian J. Pharm. Clin. Res.2019124286291
     [Google Scholar]
  41. OrtizA.C. YañezO. Salas-HuenuleoE. MoralesJ.O. Development of a nanostructured lipid carrier (NLC) by a low-energy method, comparison of release kinetics and molecular dynamics simulation.Pharmaceutics202113453110.3390/pharmaceutics13040531 33920242
     [Google Scholar]
  42. SachanA.K. GuptaA. AroraM. Formulation & characterization of nanostructured lipid carrier (NLC) based gel for topical delivery of etoricoxib.J. Drug Deliv. Ther.20166241310.22270/jddt.v6i2.1222
     [Google Scholar]
  43. GargN.K. TandelN. BhadadaS.K. TyagiR.K. Nanostructured lipid carrier–mediated transdermal delivery of aceclofenac hydrogel present an effective therapeutic approach for inflammatory diseases.Front. Pharmacol.20211271361610.3389/fphar.2021.713616 34616297
     [Google Scholar]
  44. ChhowalaI.S. JaniD.M. DharamsiA. ShindheG. PatelR. Formulation and evaluation of nano particulate drug delivery system for an effective treatment of acne.Int. J. Pharm. Res. Technol.2018821426
     [Google Scholar]
  45. SanapG.S. MohantaG.P. Design and evaluation of miconazole nitrate loaded nanostructured lipid carriers (NLC) for improving the antifungal therapy.J. Appl. Pharm. Sci.2013314654
     [Google Scholar]
  46. LiQ. CaiT. HuangY. ZhangR. ColeS.P.C. CaiY. The preparation and evaluation of cepharanthine-nanostructured lipid carriers in vitro and in vivo.J. Biomater. Tissue Eng.20177984885710.1166/jbt.2017.1642
     [Google Scholar]
  47. PatelD. DasguptaS. DeyS. RamaniY.R. RayS. MazumderB. Nanostructured lipid carriers (NLC)-based gel for the topical delivery of aceclofenac: Preparation, characterization, and in vivo evaluation.Sci. Pharm.201280374976410.3797/scipharm.1202‑12 23008819
     [Google Scholar]
  48. MadanJ.R. KhobaragadeS. DuaK. AwasthiR. Formulation, optimization, and in vitro evaluation of nanostructured lipid carriers for topical delivery of Apremilast.Dermatol. Ther.2020333e1337010.1111/dth.13370 32250507
     [Google Scholar]
  49. BhattS. SharmaJ.B. KambojR. KumarM. SainiV. MandgeS. Design and optimization of febuxostat-loaded nano lipid carriers using full factorial design.Turk. J. Pharm. Sci.2021181616710.4274/tjps.galenos.2019.32656 33633486
     [Google Scholar]
  50. FernandesA.V. PydiC.R. VermaR. JoseJ. KumarL. Design, preparation and in vitro characterizations of fluconazole loaded nanostructured lipid carriers.Braz. J. Pharm. Sci.202056e1806910.1590/s2175‑97902019000318069
     [Google Scholar]
  51. PathakP. NagarsenkerM. Formulation and evaluation of lidocaine lipid nanosystems for dermal delivery.AAPS PharmSciTech200910398599210.1208/s12249‑009‑9287‑1 19641997
     [Google Scholar]
  52. HuangW. DouH. WuH. SunZ. WangH. HuangL. Preparation and characterisation of nobiletin-loaded nanostructured lipid carriers.J. Nanomater.2017201710.1155/2017/2898342
     [Google Scholar]
  53. RahmanH. RasedeeA. HowC.W. AbdulA.B. AllaudinZ.N. OthmanH. SaeedM. YeapS. Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect.Int. J. Nanomedicine201382769278110.2147/IJN.S45313 23946649
     [Google Scholar]
  54. ShirishaS. SaraswathiA. SahooS.K. RaoY.M. Formulation and evaluation of nisoldipine loaded solid lipid nanoparticles and nanostructured lipid carriers: Application to transdermal delivery.Indian J. Pharm. Educ. Res.2020542ss117s12710.5530/ijper.54.2s.68
     [Google Scholar]
  55. BhatiaM. SrivastavM. DeviS. SharmaS. SainiK. Optimization and evaluation of ketoconazole loaded nanostructured lipid carriers employing microwave-assisted technique.Indian J. Pharm. Sci.2022841162172
     [Google Scholar]
  56. PugliaC. LauroM.R. OffertaA. CrascìL. MicicchèL. PanicoA.M. BoninaF. PuglisiG. Nanostructured lipid carriers (NLC) as vehicles for topical administration of sesamol: In vitro percutaneous absorption study and evaluation of antioxidant activity.Planta Med.2017835398404 27124246
     [Google Scholar]
  57. GuilhermeV.A. RibeiroL.N.M. AlcântaraA.C.S. CastroS.R. Rodrigues da SilvaG.H. da SilvaC.G. BreitkreitzM.C. Clemente-NapimogaJ. MacedoC.G. AbdallaH.B. BonfanteR. CeredaC.M.S. de PaulaE. Improved efficacy of naproxen-loaded NLC for temporomandibular joint administration.Sci. Rep.2019911116010.1038/s41598‑019‑47486‑w 31371737
     [Google Scholar]
  58. UpritS. Kumar SahuR. RoyA. PareA. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia.Saudi Pharm. J.201321437938510.1016/j.jsps.2012.11.005 24227958
     [Google Scholar]
  59. BawazeerS. El-TelbanyD.F.A. Al-SawahliM.M. ZayedG. KeedA.A.A. AbdelazizA.E. Abdel-NabyD.H. Effect of nanostructured lipid carriers on transdermal delivery of tenoxicam in irradiated rats.Drug Deliv.20202711218123010.1080/10717544.2020.1803448 32772730
     [Google Scholar]
  60. AlamS. AslamM. KhanA. ImamS.S. AqilM. SultanaY. AliA. Nanostructured lipid carriers of pioglitazone for transdermal application: From experimental design to bioactivity detail.Drug Deliv.201623260160910.3109/10717544.2014.923958 24937378
     [Google Scholar]
  61. BeloquiA. SolinísM.Á. RieuxA. PréatV. Rodríguez-GascónA. Dextran–protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs.Int. J. Pharm.20144681-210511110.1016/j.ijpharm.2014.04.027 24746410
     [Google Scholar]
  62. RajS.B. ChandrasekharK.B. ReddyK.B. Formulation, in-vitro and in-vivo pharmacokinetic evaluation of simvastatin nanostructured lipid carrier loaded transdermal drug delivery system.Future J. Pharm. Sci.201951114
     [Google Scholar]
  63. RanpiseN.S. KorabuS.S. GhodakeV.N. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.Colloids Surf. B Biointerfaces2014116818710.1016/j.colsurfb.2013.12.012 24445002
     [Google Scholar]
  64. SütőB. BerkóS. KozmaG. KukoveczÁ. Budai-SzűcsM. ErősG. KeményL. Sztojkov-IvanovA. GáspárR. CsányiE. Development of ibuprofen-loaded nanostructured lipid carrier-based gels: Characterization and investigation of in vitro and in vivo penetration through the skin.Int. J. Nanomedicine20161112011212 27099487
     [Google Scholar]
  65. BaekJ.S. PhamC.V. MyungC.S. ChoC.W. Tadalafil-loaded nanostructured lipid carriers using permeation enhancers.Int. J. Pharm.2015495270170910.1016/j.ijpharm.2015.09.054 26423175
     [Google Scholar]
  66. GhazyE. AbdulrasoolA.A. Al-TamimiJ.J. AyashN. Nebivolol hydrochloride loaded nanostructured lipid carriers as transdermal delivery system:-Part 2:-Hydrogel preparation, evaluation and permeation study.TOFIQ J. Med. Sci.201632116
     [Google Scholar]
  67. GuX. ZhangW. LiuJ. ShawJ.P. ShenY. XuY. LuH. WuZ. Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells.AAPS PharmSciTech20111241200120810.1208/s12249‑011‑9668‑0 21927961
     [Google Scholar]
  68. ElnaggarY. El-MassikM.A. AbdallahO.Y. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles.Int. J. Nanomedicine201163195320510.2147/IJN.S25825 22238508
     [Google Scholar]
  69. HuF.Q. JiangS.P. DuY.Z. YuanH. YeY.Q. ZengS. Preparation and characteristics of monostearin nanostructured lipid carriers.Int. J. Pharm.20063141838910.1016/j.ijpharm.2006.01.040 16563671
     [Google Scholar]
  70. PatelD.K. TripathyS. NairS.K. KesharwaniR. Nanostructured lipid carrier (Nlc) a modern approach for topical delivery: A review.World J. Pharm. Pharm. Sci.20132921938
     [Google Scholar]
  71. TeeranachaideekulV. BoonmeP. SoutoE.B. MüllerR.H. JunyaprasertV.B. Influence of oil content on physicochemical properties and skin distribution of Nile red-loaded NLC.J. Control. Release2008128213414110.1016/j.jconrel.2008.02.011 18423768
     [Google Scholar]
  72. SchäferkortingM. MehnertW. KortingH. Lipid nanoparticles for improved topical application of drugs for skin diseases.Adv. Drug Deliv. Rev.200759642744310.1016/j.addr.2007.04.006 17544165
     [Google Scholar]
  73. MüllerR. PetersenR. HommossA. PardeikeJ. Nanostructured lipid carriers (NLC) in cosmetic dermal products.Adv. Drug Deliv. Rev.200759652253010.1016/j.addr.2007.04.012 17602783
     [Google Scholar]
  74. RicciM. PugliaC. BoninaF. GiovanniC.D. GiovagnoliS. RossiC. Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC): In vitro and in vivo studies.J. Pharm. Sci.20059451149115910.1002/jps.20335 15793804
     [Google Scholar]
  75. ShahK. DateA. JoshiM. PatravaleV. Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery.Int. J. Pharm.20073451-216317110.1016/j.ijpharm.2007.05.061 17644288
     [Google Scholar]
  76. JenningV. GohlaS.H. Encapsulation of retinoids in solid lipid nanoparticles (SLN).J. Microencapsul.200118214915810.1080/02652040010000361 11253932
     [Google Scholar]
  77. ChauhanI. YasirM. VermaM. SinghA.P. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery.Adv. Pharm. Bull.202010215016510.34172/apb.2020.021 32373485
     [Google Scholar]
  78. LooCh. BasriM. IsmailR. LauH. TejoB. KanthimathiM. HassanH. ChooY. Effect of compositions in nanostructured lipid carriers (NLC) on skin hydration and occlusion.Int. J. Nanomedicine201381322 23293516
     [Google Scholar]
  79. JunyaprasertV.B. TeeranachaideekulV. SoutoE.B. BoonmeP. MüllerR.H. Q10-loaded NLC versus nanoemulsions: Stability, rheology and in vitro skin permeation.Int. J. Pharm.20093771-220721410.1016/j.ijpharm.2009.05.020 19465098
     [Google Scholar]
  80. GomesM.J. MartinsS. FerreiraD. SegundoM.A. ReisS. Lipid nanoparticles for topical and transdermal application for alopecia treatment: Development, physicochemical characterization, and in vitro release and penetration studies.Int. J. Nanomedicine2014912311242 24634584
     [Google Scholar]
  81. ZhaiY. ZhaiG. Advances in lipid-based colloid systems as drug carrier for topic delivery.J. Control. Release2014193909910.1016/j.jconrel.2014.05.054 24939745
     [Google Scholar]
  82. WangJ. WangH. ZhouX. TangZ. LiuG. LiuG. XiaQ. Physicochemical characterization, photo-stability and cytotoxicity of coenzyme Q10-loading nanostructured lipid carrier.J. Nanosci. Nanotechnol.20121232136214810.1166/jnn.2012.5790 22755031
     [Google Scholar]
  83. JoresK. MehnertW. MäderK. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: A nuclear magnetic resonance and electron spin resonance study.Pharm. Res.20032081274128310.1023/A:1025065418309 12948026
     [Google Scholar]
  84. WaghuleT. RapalliV.K. GorantlaS. SahaR.N. DubeyS.K. PuriA. SinghviG. Nanostructured lipid carriers as potential drug delivery systems for skin disorders.Curr. Pharm. Des.202026364569457910.2174/1381612826666200614175236 32534562
     [Google Scholar]
  85. AlamM. RizwanullahM. MirS.R. AminS. Promising prospects of lipid-based topical nanocarriers for the treatment of psoriasis.OpenNano20231010012310.1016/j.onano.2023.100123
     [Google Scholar]
  86. GargJ. PathaniaK. SahS.P. PawarS.V. Nanostructured lipid carriers: A promising drug carrier for targeting brain tumours.Future J. Pharm. Sci.2022812510.1186/s43094‑022‑00414‑8
     [Google Scholar]
  87. StefanovS.R. AndonovaV.Y. Lipid nanoparticulate drug delivery systems: Recent advances in the treatment of skin disorders.Pharmaceuticals20211411108310.3390/ph14111083 34832865
     [Google Scholar]
  88. YuanS. ChenJ. FengS. LiM. SunY. LiuY. Combination anesthetic therapy: Co-delivery of ropivacaine and meloxicam using transcriptional transactivator peptide modified nanostructured lipid carriers in vitro and in vivo.Drug Deliv.202229126326910.1080/10717544.2021.2023695 35014916
     [Google Scholar]
  89. PaleiN.N. MohantaB.C. DasM.K. SabapathiM.L. Lornoxicam loaded nanostructured lipid carriers for topical delivery: Optimization, skin uptake and in vivo studies.J. Drug Deliv. Sci. Technol.20173949050010.1016/j.jddst.2017.05.001
     [Google Scholar]
  90. ChenC.Y. LeeY.H. ChangS.H. TsaiY.F. FangJ.Y. HwangT.L. Oleic acid-loaded nanostructured lipid carrier inhibits neutrophil activities in the presence of albumin and alleviates skin inflammation.Int. J. Nanomedicine2019146539655310.2147/IJN.S208489 31496699
     [Google Scholar]
  91. PawbakeG.R. ShirolkarS.V. Formulation, development and evaluation of nanostructured lipid carrier (NLC) based gel for topical delivery of diacerein.Syst. Rev. Pharm.2020116794802
     [Google Scholar]
  92. ZewailM. NafeeN. HelmyM.W. BoraieN. Coated nanostructured lipid carriers targeting the joints – An effective and safe approach for the oral management of rheumatoid arthritis.Int. J. Pharm.201956711844710.1016/j.ijpharm.2019.118447 31226475
     [Google Scholar]
  93. KangQ. LiuJ. ZhaoY. LiuX. LiuX.-Y. WangY.-J. MoN.-L. WuQ. Transdermal delivery system of nanostructured lipid carriers loaded with Celastrol and Indomethacin: Optimization, characterization and efficacy evaluation for rheumatoid arthritis.Artif. Cells Nanomed. Biotechnol.201846sup3S585S59710.1080/21691401.2018.1503599
     [Google Scholar]
  94. PivettaT.P. SimõesS. AraújoM.M. CarvalhoT. ArrudaC. MarcatoP.D. Development of nanoparticles from natural lipids for topical delivery of thymol: Investigation of its anti-inflammatory properties.Colloids Surf. B Biointerfaces201816428129010.1016/j.colsurfb.2018.01.053 29413607
     [Google Scholar]
  95. NguyenC.N. NguyenT.T.T. NguyenH.T. TranT.H. Nanostructured lipid carriers to enhance transdermal delivery and efficacy of diclofenac.Drug Deliv. Transl. Res.20177566467310.1007/s13346‑017‑0415‑2 28776220
     [Google Scholar]
  96. RincónM. CalpenaA.C. ClaresB. EspinaM. Garduño-RamírezM.L. Rodríguez-LagunasM.J. GarcíaM.L. AbregoG. Skin-controlled release lipid nanosystems of pranoprofen for the treatment of local inflammation and pain.Nanomedicine201813192397241310.2217/nnm‑2018‑0195 30311846
     [Google Scholar]
  97. CamposJ. SeverinoP. SantiniA. SilvaA. ShegokarR. SoutoS. SoutoE.B. Solid lipid nanoparticles (SLN): Prediction of toxicity, metabolism, fate and physicochemical properties.NanopharmaceuticalsElsevier2020111510.1016/B978‑0‑12‑817778‑5.00001‑4
     [Google Scholar]
  98. BrugèF. DamianiE. MarcheggianiF. OffertaA. PugliaC. TianoL. A comparative study on the possible cytotoxic effects of different nanostructured lipid carrier (NLC) compositions in human dermal fibroblasts.Int. J. Pharm.2015495287988510.1016/j.ijpharm.2015.09.033 26392245
     [Google Scholar]
  99. RahmanH.S. RasedeeA. OthmanH.H. ChartrandM.S. NamvarF. YeapS.K. Abdul SamadN. AndasR.J. Muhammad NadzriN. AnasamyT. Acute toxicity study of zerumbone-loaded nanostructured lipid carrier on BALB/c mice model.BioMed Res. Int.20142014
     [Google Scholar]
  100. AkandaM.H. RaiR. SlipperI.J. ChowdhryB.Z. LamprouD. GettiG. DouroumisD. Delivery of retinoic acid to LNCap human prostate cancer cells using solid lipid nanoparticles.Int. J. Pharm.20154931-216117110.1016/j.ijpharm.2015.07.042 26200751
     [Google Scholar]
/content/journals/aiaamc/10.2174/0118715230311633240708075738
Loading
Topical Administration of Nanostructured Lipid Carriers as a Viable Approach to Reduce Inflammation: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents) 24, 26 (2025); https://doi.org/10.2174/0118715230311633240708075738
/content/journals/aiaamc/10.2174/0118715230311633240708075738
/content/journals/aiaamc/10.2174/0118715230311633240708075738
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): arthritis; inflammation; lipids; Nanomaterials; nanostructured lipid carriers; targeted drug delivery

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test